Tryptophan degradation and immune activation in Alzheimer's disease

2000 ◽  
Vol 107 (3) ◽  
pp. 343-353 ◽  
Author(s):  
B. Widner ◽  
F. Leblhuber ◽  
J. Walli ◽  
G. P. Tilz ◽  
U. Demel ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation ◽  
Tryptophan Degradation

Immune activation in patients with Alzheimer's disease

1998 ◽  
Vol 8 ◽  
pp. S279
Author(s):  
F. Leblhuber ◽  
J. Walli ◽  
G.P. Tilz ◽  
B. Widner ◽  
D. Fuchs
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation

scholarly journals Innate immune activation in Alzheimer’s disease

2018 ◽  
Vol 6 (10) ◽  
pp. 177-177 ◽  
Author(s):  
Ming-Ming Wang ◽  
Dan Miao ◽  
Xi-Peng Cao ◽  
Lin Tan ◽  
Lan Tan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation ◽  
Innate Immune ◽  
Innate Immune Activation

Peripheral Immune Activation in Alzheimer's Disease

Pteridines ◽  
2000 ◽  
Vol 11 (2) ◽  
pp. 48-53
Author(s):  
Friedrich Leblhuber ◽  
Johannes Walli ◽  
Gernot P. Tilz ◽  
Ulrike Demel ◽  
Bernhard Widner ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation ◽  
Interleukin 2 ◽  
Tumor Necrosis Factor Receptor ◽  
Inverse Correlation ◽  
Serum Concentrations ◽  
Complement Components ◽  
Activation Markers ◽  
Severity Of Dementia

AbstractIn fifty-four patients with Alzheimer's disease [AD (14 males, 40 females, age 77.1 2: 7.4 years)], free of any infection and twenty-two age-matched healthy controls with normal mental status (9 males, 13 females, age 74.9 ± 9.0 years) serum concentrations of soluble parameters of immune activation including neopterin, 55 kDa-type soluble tumor necrosis factor receptor (sTNF-RSS), soluble interleukin-2 receptor (sIL-2R), immunoglobulins A, M and G, complement components C3 and C4, circulating immune complexes, and soluble CD23 as well as a panel of routine laboratory tests were determined. Compared to controls, significantly higher concentrations of sIL-2R (p < 0.01), neopterin (p < 0.01), sTNF-R55. sCD23 and IgA (all p < O.OS) were found in AD patients. Patients with greater cognitive impairment had higher concentrations of neopterin and sTNF-R55. An inverse correlation was seen between mini mental state (MMS) and sTNF-R55 (r = -0.43S; P < 0.01) and neopterin (rs = -0.289; P < 0.05). Our data show increased serum concentrations of immune activation markers in patients with AD correlating with the severity of dementia. Increased neopterin concentrations together with increased slNF-R55 and sIL-2R imply a chronic state of peripheral immune activation in the course of AD. Our data underscore previous reports on the effect of anti-inflammatory drugs in therapy and prevention of AD.

On the Possible Relevance of Bottom-up Pathways in the Pathogenesis of Alzheimer’s Disease

2020 ◽  
Vol 20 (15) ◽  
pp. 1415-1421 ◽  
Author(s):  
Friedrich Leblhuber ◽  
Kostja Steiner ◽  
Simon Geisler ◽  
Dietmar Fuchs ◽  
Johanna M. Gostner
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Deficits ◽  
Immune Activation ◽  
Significant Proportion ◽  
Microbiome Composition ◽  
Age Related ◽  
Value Changes ◽  
Systemic Infections ◽  
The Brain

Dementia is an increasing health problem in older aged populations worldwide. Age-related changes in the brain can be observed decades before the first symptoms of cognitive decline appear. Cognitive impairment has chronic inflammatory components, which can be enhanced by systemic immune activation. There exist mutual interferences between inflammation and cognitive deficits. Signs of an activated immune system i.e. increases in the serum concentrations of soluble biomarkers such as neopterin or accelerated tryptophan breakdown along the kynurenine axis develop in a significant proportion of patients with dementia and correlate with the course of the disease, and they also have a predictive value. Changes in biomarker concentrations are reported to be associated with systemic infections by pathogens such as cytomegalovirus (CMV) and bacterial content in saliva. More recently, the possible influence of microbiome composition on Alzheimer’s disease (AD) pathogenesis has been observed. These observations suggest that brain pathology is not the sole factor determining the pathogenesis of AD. Interestingly, patients with AD display drastic changes in markers of immune activation in the circulation and in the cerebrospinal fluid. Other data have suggested the involvement of factors extrinsic to the brain in the pathogenesis of AD. However, currently, neither the roles of these factors nor their importance has been clearly defined.

F4-06-02: INSIGHTS FROM CLINICAL RESEARCH ON THE TIMING AND TRAJECTORY OF IMMUNE ACTIVATION IN ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_26) ◽  
pp. P1391-P1391
Author(s):  
Clive Holmes ◽  
Rebecca Sussams ◽  
Alexander Gerhard ◽  
Karl Herholz ◽  
Andreas H. Jacobs ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Research ◽  
Immune Activation

Alzheimer's disease and immune activation: A translational perspective

2004 ◽  
Vol 35 (3) ◽  
pp. 193-201
Author(s):  
Paola Bossù ◽  
Antonio Ciaramella ◽  
M. Luisa Moro ◽  
Gianfranco Spalletta ◽  
Carlo Caltagirone
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation

3-12-14 Immune activation in patients with Alzheimer's disease

1997 ◽  
Vol 150 ◽  
pp. S156
Author(s):  
F. Leblhuber ◽  
D. Fuchs ◽  
J. Walli ◽  
G.P. Tilz ◽  
H. Wachter
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation

scholarly journals Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples

2019 ◽  
Vol 138 (4) ◽  
pp. 613-630 ◽  
Author(s):  
Stefan Prokop ◽  
Kelly R. Miller ◽  
Sergio R. Labra ◽  
Rose M. Pitkin ◽  
Kevt’her Hoxha ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immune Activation ◽  
Brain Region ◽  
Disease Patient ◽  
Risk Variants
Sign in / Sign up

Export Citation Format

Share Document